Kerecis and the US Department of Defence have entered an agreement to develop fish skin burn treatment.

As part of the agreement, Kerecis will modify and test its existing fish skin technology in curing the burn injuries through preclinical and clinical studies, while the US Army Medical Research and Material Command will be responsible for funding the research programme.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The agreement enables Kerecis to introduce new treatment for burn wounds.

PharmaJet and Vaccibody have entered a co-development agreement to develop a needle-free human papillomavirus (HPV) vaccine.

"PharmaJet and Vaccibody have entered a co-development agreement to develop a needle-free human papillomavirus (HPV) vaccine."

The two partners will jointly work on developing the needle-free injection to deliver the HPV vaccine.

Fimbrion Therapeutics and GlaxoSmithKline have entered an agreement to develop new antibacterial therapies for urinary tract infections (UTIs).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The two partners will work on a project focused on developing small molecule compounds for the treatment of UTIs.

The agreement enables the partners to treat and prevent UTIs using mannosides.

Pluristem Therapeutics plans to raise gross proceeds of $30m through the private placement of 16.8 million of its common stock shares.

The placement will be subscribed to by Innovative Medical Management.

Pluristem plans to invest the funds to further advance the late-stage trials for its cell therapies.

Everstone Capital Management has acquired a 70% stake in Rubicon Research for a purchase consideration of $33m.

The transaction allows Rubicon Research to further advance its growth strategy.